HLF and cancer: According to the findings, cancer patients with an overexpression of the HLF gene may be resistant to CAL-101 and Navitoclax but responsive to Paclitaxel, Dasatinib, Docetaxel, AZ628, Z-LLNle-CHO, WH-4-023, Bortezomib, Bleomycin (50 μM), 17-AAG, MLN4924, Vinblastine, YM155, Vinorelbine, CI-1040 (Fig. 6).